Loading...
•
Dec 31, 2022
Ocular Therapeutix Q4 2022 Earnings Report
Ocular Therapeutix reported Q4 2022 earnings, showing revenue growth and pipeline advancement.
Key Takeaways
Ocular Therapeutix reported total net revenue of $14.1 million for Q4 2022, representing a 15% increase year-over-year. The company's net loss for the quarter was $(15.5) million, which included a $5.2 million non-cash item. DEXTENZA net product revenue was $13.9 million, a 14% increase over the comparable quarter of 2021. The company is progressing with its pipeline, including OTX-TKI and OTX-TIC, and expects key milestones in 2023.
Total net revenue for Q4 2022 was $14.1 million, up 15% year-over-year.
DEXTENZA net product revenue in Q4 2022 was $13.9 million, a 14% increase over the comparable quarter of 2021.
The company reported a net loss of $(15.5) million for Q4 2022, including a $5.2 million non-cash item.
Ocular Therapeutix is advancing its pipeline, including OTX-TKI and OTX-TIC, with key milestones expected in 2023.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Ocular Therapeutix estimates DEXTENZA Net Product Revenue for the year ending 2023 to be between $55 and $60 million, representing growth of approximately 10% to 20% over the prior year.